INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Tr...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- -- DNA immunotherapy candidate VGX-3100 demonstrated resolution of HPV-16/18-associated precancerous anal lesions in 50% of treated patients six months after treatment -- Current standard of care for anal dysplasia typically requires surgical ...
Authors: LATEST ASIANET NEWS RELEASES